20
KIT
Making Progress
A brief update on various diabetes kit developments.
By Sue Marshall.
Abbott
Abbott received FDA clearance for its FreeStyle Libre 2
iOS application for use with compatible iPhones in August
2021, as reported by Drug Delivery News.
The company designed the new FreeStyle Libre 2 app
to enable users to get glucose readings directly on their
iPhones without the use of a reader, allowing caregivers
to remotely monitor glucose readings and get real-time
alarms through the LibreLinkUp app.
FDA clearance allows use of the app for adults and
children four years of age and older with diabetes,
according to a news release. The app offers personalized,
up-to-the-minute glucose data for those with diabetes
who are using FreeStyle Libre 2 glucose sensors.
By scanning their sensor with the app, users can
obtain their current glucose reading and trend arrow
to help determine how food, exercise and more impact
their diabetes management. Abbott diabetes care SVP
Jared Watkin said at the time, "The demands of living
with diabetes can be overwhelming, and there's a critical
need to improve the way people with diabetes manage
their condition - easily, affordably, accurately - and in
a way that seamlessly fits into their everyday lives. The
FreeStyle Libre 2 iOS app streamlines how people manage
their diabetes on their iPhones - empowering users with
the information they need 24/7 while improving their
health on the go."
www.freestylelibre.co.uk
Air Liquide
Tandem is first smartphone App to be cleared for insulin
delivery by the FDA on both iOS and Android operating
systems. Announced in mid-February 2022, the clearance
is of bolus insulin dosing on the t:slim X2 insulin pump
using the t:connect mobile app. This represents the
first-ever FDA-cleared smartphone application capable
of initiating insulin delivery on both iOS and Android
operating systems. The updated t:connect mobile app is
designed to offer t:slim X2 insulin pump users the ability
to program and cancel bolus insulin requests through the
convenience of their compatible smartphone.
"This FDA clearance further validates our commitment
to innovation and the diabetes community by providing
one of the most requested feature enhancements," said
John Sheridan, president and CEO of Tandem Diabetes
Care. "With the improvements in diabetes management
provided by Tandem's Control-IQ technology, giving a
meal bolus is now the most common reason a person
interacts with their pump, and the ability to do so using
a smartphone app offers a convenient and discrete
solution."
When released, this new feature will be offered in
the United States for no additional cost to new t:slim X2
insulin pump customers and to in-warranty customers
through a remote software update for the t:slim X2
insulin pump and the updated t:connect mobile app. The
company intends to roll out the mobile bolus feature
update in a series of limited launch groups, followed by an
expanded launch later this summer.
In addition to the t:connect mobile app being the
first to receive FDA clearance on both iOS and Android
operating systems to deliver insulin from a personal
smartphone, Tandem was also the first to receive an
interoperable automated glycaemic controller designation
with Control-IQ technology in December 2019, the first
to receive an alternate controller-enabled infusion pump
classification in February 2019, and the first insulin pump
designated as compatible with integrated continuous
glucose monitoring devices in June 2018.
www.makingdiabeteseasier.com
CeQur
We've covered this on-body patch pump before but the
design has evolved since our last coverage and progress
is being made in the United States to get people with
diabetes on the technology. The company says that its
CeQur Simplicity is a revolutionary patch that delivers
injection-free mealtime insulin. It's not a pen. It's not a
pump. It's a wearable insulin patch. Using a tiny, flexible
cannula, you can deliver rapid-acting insulin under
your skin. It changes the way you dose for meals and
correction boluses, eliminating the need for multiple
daily injections. Missing insulin doses has been shown to
CeQur patch early 2022.